Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Share-based Compensation (2023 - 2025)

Historic Share-based Compensation for Camp4 Therapeutics (CAMP) over the last 3 years, with Q3 2025 value amounting to $984000.0.

  • Camp4 Therapeutics' Share-based Compensation fell 3819.1% to $984000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.6 million, marking a year-over-year decrease of 583.98%. This contributed to the annual value of $4.0 million for FY2024, which is 3869.97% up from last year.
  • According to the latest figures from Q3 2025, Camp4 Therapeutics' Share-based Compensation is $984000.0, which was down 3819.1% from $1.0 million recorded in Q2 2025.
  • Camp4 Therapeutics' Share-based Compensation's 5-year high stood at $1.6 million during Q3 2024, with a 5-year trough of $636000.0 in Q4 2023.
  • Moreover, its 3-year median value for Share-based Compensation was $856000.0 (2024), whereas its average is $915111.1.
  • Per our database at Business Quant, Camp4 Therapeutics' Share-based Compensation surged by 12049.86% in 2024 and then crashed by 3819.1% in 2025.
  • Quarter analysis of 3 years shows Camp4 Therapeutics' Share-based Compensation stood at $636000.0 in 2023, then rose by 25.31% to $797000.0 in 2024, then increased by 23.46% to $984000.0 in 2025.
  • Its Share-based Compensation was $984000.0 in Q3 2025, compared to $1.0 million in Q2 2025 and $861000.0 in Q1 2025.